No 03 2021

The Life Science Cluster turns ten. But instead of looking in the rearview mirror, let's look at why life science will matter more over the next decade.

More than 40% of women in the US say their health has limited their career, and the share rises to 66% among women who cannot get the care they need, according to a new Gallup survey conducted in partnership with Pivotal.

The US Food and Drug Administration (FDA) has accepted and granted Priority Review to Alexion, AstraZeneca's Rare Disease unit, for efzimfotase alfa as a treatment for patients with hypophosphatasia (HPP) aged 2 years and older.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Pepaxti (melflufen) be extended to earlier lines of multiple myeloma treatment, a move that would significantly widen the drug's eligible patient population.

Teitur Trophics' co-founder and CEO Simon Mølgaard was named Rising Star in Danish Biotech at the DANISH BIO – Dansk Biotek Spring Gala in April 2026. Nordic Life Science asked him about the transition from science to business, building a company from Aarhus, and the opportunities ahead in treating neurodegenerative disease.

Orbis Medicines has entered a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases, in a deal worth up to USD 1.4 billion.

Over the course of her career, Anna Sundin has worked on numerous transactions spanning capital raises, IPOs, M&A, and debt financing, as well as providing strategic advice to companies in a growth phase.